Arena Pharmaceuticals Announces Achievement of a $3 Million Milestone Under Merck Collaboration for Assay Development
San Diego. Arena Pharmaceuticals, Inc. announced the achievement of a $3 million milestone from Merck & Co., Inc. for assay development under their cardiovascular collaboration.
In 2002, Arena and Merck entered into a collaboration focused on a group of GPCR targets discovered by Arena, which may represent novel targets for cardiovascular disease. Arena announced in the first quarter of 2004 the achievement of a $4 million milestone under this collaboration related to animal testing of small molecules in this program.
"We are pleased with Merck's commitment to the cardiovascular program and their further validation of our GPCR research programs," commented Dr. Dominic P. Behan, Arena's co-founder, Senior Vice President and Chief Scientific Officer. "We look forward to continuing our work with Merck to achieve our mutual goal of developing a successful product to treat cardiovascular disease."
Most read news
Organizations
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.